Utilizing the Molecular/Physiologic Phenotype to Direct Asthma Therapy: A Comprehensive 3-Dimensional Study

Thursday, November 15, 2018
6:30 PM – 8:00 PM


Sheraton Seattle Hotel
1400 6th Ave, Seattle, WA 98101
Metropolitan Ballroom
Meeting Room: Salon B – 3rd FL


Already Registered?


In conjunction with the 2018 ACAAI Annual Meeting



Thursday, November 15, 2018

9:30 PM Eastern    8:30 PM Central    7:30 PM Mountain    6:30 PM Pacific

Add to Calendar 11/15/2018 09:30 PM 11/15/2018 11:00 PM America/New_York Utilizing the Molecular/Physiologic Phenotype to Direct Asthma Therapy: A Comprehensive 3-Dimensional Study Utilizing the Molecular/Physiologic Phenotype to Direct Asthma Therapy: A Comprehensive 3-Dimensional Study Live Simulcast Med Learning Group info@medlearninggroup.com false MM/DD/YYYY atZOdzeAgzXtBkKLjmOo27579



  • Create your own Personalized Poster
  • Interactive, case-based learning environment
  • 3D videos and glasses for all attendees


Jonathan Corren, MD
Director Allergy Medical Center
Associate Professor Department of Internal Medicine
UCLA Medical Center
Los Angeles, CA

Michael E. Wechsler, MD, MMSc
Director, Asthma Program
Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


I. Severe asthma: Standard definitions, increased understanding of the molecular biology of inflammation, and a changing paradigm
  a. Evolving concepts of asthma as a heterogeneous condition
  b. Pathophysiology: Variation among causative factors, cells, and cell mediators

II. Basic pathology of type 2 and non-type 2 asthma
  a. Cellular phenotypes
  b. Endotypes
  c. How to assess characteristics in practical clinic setting

III. How endotype and phenotype informs/will inform treatment decisions and lead to personalized treatment therapy

IV. Treatment guidelines: The “one size fits all” treatment guidelines vs nuances of genome

V. Approved therapies
  • Biomarkers and targeted therapies:
    a. Benralizumab
    b. Mepolizumab
    c. Omalizumab
    d. Reslizumab

VI. Approved procedure: Bronchial thermoplasty

VII. Potential therapies
  a. Dupilumab
  b. Fevipiprant
  c. Tezepelumab



After completing the CME activity, learners should be better able to:

  • Assess the causes of underlying inflammation in asthma, and resulting targets of therapy
  • Evaluate the level of asthma control, disease severity, and exacerbation risk to better drive appropriate treatment
  • Review currently-available and novel targeted therapies and their effect on treatment strategies for patients with moderate-to-severe asthma


This CME initiative is designed to meet the educational needs of pulmonologists, allergists, immunologists and primary care physicians who are involved in the healthcare of patients with severe asthma.


In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


Med Learning Group makes every effort to develop CME activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

“The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology”.


Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Feel free to pass this invitation on to your physicians, fellows, physician assistants, nurses, pharmacists, healthcare practitioners, and any other colleagues that you believe would be interested in attending this free CME/CNE program.



Please use the following form to register for this webcast. You will receive an email confirmation shortly after you complete the registration.

If you are unable to register online or do not receive your confirmation email after registering, please email us at support@performedia.com.

Registration Form

*Required field


Please enter your registered email and click the Sign In button to watch the Live Simulcast.

If you are unable to sign in or watch the live simulcast, please email us at support@performedia.com.




Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.